Ulviprubart not checked

Abcuro, Inc. · ABC008

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2/3 trial completes
Trials
1 active
4 in total · 2 in the EU
Targets
 

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-bart: artificial immunoglobulins WHO name stem
How it’s given
“All eligible subjects, regardless of treatment assignment or dose level in their initial study, will be administered ulviprubart at a dose of 2.0 mg/kg via subcutaneous (SC) injection Q8W.”In the company’s words, NCT06450886 on ClinicalTrials.gov
Tested for
Inclusion Body Myositis (IBM)
Main trialPhase 2/3
“ABC008-IBM-202 is an open-label, multicenter study to evaluate the safety and efficacy of long-term administration of ulviprubart (ABC008) in subjects with IBM who have completed either Study ABC008-IBM-101 or Study ABC008-IBM-201. Subjects may be enrolled in this study if they meet study eligibility criteria and: * Have completed the Part 2 (Multiple Ascending Dose \[MAD\]) End of-Treatment (EOT) Visit in Study ABC008-IBM-101; subjects who continued further on into Part 3 of the study (MAD Extension) prior to enrolling in this study are also eligible; OR * Have completed the Week 80…”In the company’s words, NCT06450886 on ClinicalTrials.gov
Other names
ABC008

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 2/3Active, not recruiting Jan 2029 Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis
Phase 2/3Completed 6 Nov 2025 A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis
Phase 1/2Completed 28 Aug 2025 ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL)
Phase 1Completed 10 Jan 2025 A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Ulviprubart

Following is part of Solo: you see every change to Ulviprubart the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in